JERSEY CITY, N.J., Sept. 25, 2018 /PRNewswire/ -- TrialScope, the global leader in clinical trial transparency and compliance solutions, today announced the launch of its Clinical Trial Transparency Service (CTTS). This transparency and health literacy management solution enables clinical trial sponsors to engage with patients, healthcare professionals, researchers and the public via a dedicated clinical trial informational website. The company is debuting this service with three customers that are among the top 20 pharmaceutical companies in the world.
As the demand for accurate and understandable clinical trial transparency from regulatory and patient advocacy groups continues to grow, TrialScope's CTTS allows sponsors to position themselves as pioneers in trial data sharing, trial literacy, trial recruitment optimization, patient education and retention. In addition, under the new service, the sponsor's website is automatically updated with information submitted to Clinicaltrials.gov, eliminating redundant processes and associated costs, and improving reporting accuracy.
"Today, more than ever, patients are seeking clinical trial information on the web. This, coupled with calls for transparency, highlights a major need in the industry for a way to disseminate important, easy-to-understand information such as plain language summaries (PLS), or respond to data requests," said Jeff Kozloff, CEO of TrialScope. "We're excited to share our newest solution with the clinical trial community and look forward to helping sponsors deliver meaningful clinical trial data and clear communications to help patients find, share, enroll and stay engaged in studies."
CTTS leverages digital and mobile platforms, social media and patient engagement to deliver an unprecedented opportunity for clinical trial sponsors, participants and researchers to find each other with greater speed and precision. In addition, CTTS enables more meaningful engagement, which can help accelerate the process of clinical trial recruitment.
CTTS offers a variety of benefits to both patients and sponsors, including:
CTTS is available immediately to sponsors and is easily integrated with TrialScope's other offerings, or external systems. For quick deployment, sponsors can select from a number of best practice website design templates. Sponsors can also work directly with TrialScope to develop a custom layout and design.
For more information on TrialScope or its Clinical Trial Transparency Service, visit trialscope.com.
About TrialScope
TrialScope is the global leader in clinical trial disclosure and transparency management technology, supporting 13 of the top 15 industry clinical trial sponsors worldwide. TrialScope provides proven solutions that are designed to optimize the efficiency of disclosure activities, maximize trial data transparency, and foster more informed, engaged patients through open research sharing. To learn more about TrialScope, visit trialscope.com.
SOURCE TrialScope
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.